Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | THRB | P10828 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734390 | 0.89 | TP53 (0.70) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22735808 | 0.88 | TDP1 (0.72) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22735639 | 0.81 | THRB (0.78) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22734759 | 0.79 | THRB (0.69) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22734475 | 0.79 | THRB (0.68) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22735620 | 0.79 | TP53 (0.69) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22734709 | 0.78 | THRB (0.72) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22735676 | 0.78 | THRB (0.63) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22735789 | 0.77 | THRB (0.62) | TP53TDP1LMNATHRBMAPT | |
| SCHEMBL22400676 | 0.77 | MAPT (0.72) | TP53LMNATHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-23 | — | — | US | disclosed |
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | BET1, BRD4, BRD3 | TP53 1128/4885TDP1 821/4885LMNA 2598/4885 |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | BET1, BRD4, BRD3 | TP53 1349/4885TDP1 858/4885LMNA 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.